Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Adult Patients With Bullous Pemphigoid
NCT04206553Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2020
- Primary completion
- Jul 2024
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in Bullous Pemphigoid (BP) comparing dupilumab with Matching placebo (2 arms). Primary endpoint: Percent of Participants Achieving Sustained Remission at 52 weeks. Started Oct 2020; status: completed.
02
Drugs
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on NCT04206553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04206553.